Interpreting 7-Year Valve Durability in PARTNER 3—Reply - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply: Interpreting Seven-Year Valve Durability Findings From PARTNER 3

  • By

  • Philippe Pibarot

  • Julien Ternacle

  • Rebecca Hahn

  • November 1, 2026

Share

  • 1

    PARTNER 3 allowed surgeons to select the bioprosthetic valve they considered best for each patient, reflecting contemporary standard-of-care practice during enrollment.

  • 2

    After Trifecta and Mitroflow valves were excluded, all-cause bioprosthetic valve failure rates were comparable for TAVR and surgery (6.9% vs 5.4%; P = .42).

  • 3

    Structural valve deterioration–related failure rates were also comparable between TAVR and surgery after those valves were excluded (3.9% vs 3.4%; P = .69).

  • 4

    The authors favor all-cause bioprosthetic valve failure over reintervention alone as a durability measure because it also captures valve-related death and irreversible severe dysfunction.

  • 5

    Mechanical valve replacement was largely infeasible in PARTNER 3: no participants were younger than 50 years, and only 9.5% were aged 50 to 65 years.

Original Source(s)

Related Content